zanubrutinib,obinutuzumab
beigene,roche,biogen
['lymsm', 'rosewood']
rosewood trial (zinzani) - obi vs obi+zanu rel fl
- 2+ lines prior rx, crossover allowed
- slightly higher risk gp in obi arm
- orr 68% v 46%
- med pfs 27mo v 11mo
- os &amp; ttnt benefit
- no surprises with safety
some activity of btki in fl, not always seen! #eha2022 #eha22 #lymsm 
Lymphoma specialist at Oxford Cancer and Haematology centre. Haematologist and clinical trialist. Past chair of UK Hodgkin and T-cell study groups.